Clinical Trial

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YOLT-201 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM).
Trial Details
NCT Number NCT06539208
Lead Sponsor YolTech Therapeutics Co., Ltd
Conditions Transthyretin Amyloidosis Polyneuropathy, Transthyrexin Amyloidosis Cardiomyopathy
Enrollment 31 participants
Start Date 2024-05-23
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-06